Aberrant activation of YAP has been associated with poor prognosis in multiple of human cancers [5], [9]–[11], including hepatocellular, ovarian, and malignant mesothelioma, and may act as an oncogene in breast cancer [15]. This evidence concerns the gene YAP1 and breast cancer.